Trial Profile
A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Triciribine (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Prescient Therapeutics
- 17 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 08 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.